Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Monday, 01 / 24 / 2022




Drug-induced Fatty Liver Disease: Pathogenesis and Treatment

Tea Omanovic Kolaric1,2,# , Vjera Nincevic1,2,# , Lucija Kuna1,2 , Kristina Duspara1 , Kristina Bojanic1,2,3 , Sonja Vukadin1,2 , Nikola Raguz-Lucic1,2 , George Y Wu4 and Martina Smolic1,2,*

1  University of Osijek, Faculty of Medicine, Osijek, Croatia
2  University of Osijek, Faculty of Dental Medicine and Health, Osijek, Croatia
3  Health Center Osijek, Osijek, Croatia
4  Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA
#These authors contributed equally to this work.
*Correspondence to:Martina Smolic, University of Osijek, Faculty of Medicine, Department of Pharmacology; Faculty of Dental Medicine and Health, Department of Pharmacology and Biochemistry, J. Huttlera 4, Osijek 31000, Croatia. ORCID: . Tel: + 385-31-512-800, Fax: +385-31-512-833, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2021;9(5):731-737 DOI: 10.14218/JCTH.2020.00091
Received:October 10, 2020 Accepted:July 1, 2021 Published online:September 14, 2021


Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies.


Metabolic dysfunction-associated fatty liver disease, Drug-induced liver injury, Reactive oxygen species, Free fatty acids, Pharmacogenetics

Journal of Clinical and Translational Hepatology 2021 vol. 9, 731-737  [ Html  ] [ PDF Full-text ]

© 2021 Authors. This is an Open Access article distributed under the terms of the  Creative Commons Attribution-Noncommercial 4.0 License(CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


You are here: Home